Keyword: Johnson & Johnson
Edwards Lifesciences and Johnson & Johnson Vision Care have made multimillion-euro investments to boost their manufacturing capacity in Ireland.
Fusion Pharmaceuticals raised $105 million to push a clinical-stage program and build a pipeline of new treatments and combination therapies.
Johnson & Johnson Vision has launched its adaptive contacts that darken to match changing light, employing the same tech seen in Transitions lenses.
Two phase 3 studies of J&J’s antihistamine contact lens showed it reduced feelings of itchy eyes after 15 minutes and for as long as 12 hours.
The writedown comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176.
The FDA’s warning letters to breast implant manufacturers come during newly galvanized agency probes into the long-term safety of silicone implants.
Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.
The deal gives J&J an exclusive option to research, develop and commercialize AdoRx antagonists.
J&J has joined AbbVie as a partner for Morphic and its small-molecule integrin platform, pledging up to $725 million to the cause.
Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.
